Cytori Therapeutics appoints Gregg Lapointe as director
Mr. Lapointe has over 20 years of experience in the pharmaceutical and medical device industries.
Mr. Lapointe is a Co-Founder and currently serves as the CEO of Cerium Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing medicines for patients with rare diseases.
Previously, he held several managerial and executive roles at Sigma-Tau Pharmaceuticals including serving as CEO from 2008 to 2012.
Prior to that, Mr. Lapointe held various financial and operations roles at AstenJohnson, Medical Plastic Devices, Inc. and Ingram & Bell Meditron.
Prior to joining Ingram & Bell Meditron, he served as a Senior Manager at Zittrer Siblin Stein Levine, a management consultant mergers and acquisitions firm based in Montreal, Canada.
Mr. Lapointe began his career at Price Waterhouse in 1982 as a Chartered Accountant with progressive advancement from staff accountant to Audit Manager.
Mr. Lapointe received a Bachelor of Commerce degree from Concordia University, a Graduate Diploma in Public Accountancy from McGill University and an MBA from Duke University. He is a Certified Public Accountant in Illinois.
He currently serves as a member of the Board of Directors of SciClone Pharmaceuticals, Soligenix and Immunocellular Therapeutics and on the Board of Trustees of the Keck Graduate Institute of Applied Life Sciences.
Mr. Lapointe has previously served on the Board and as Chair of the Rare Disease Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Board of Directors of Questcor Pharmaceuticals and Raptor Pharmaceutical Corp. ■
LATEST MOVES FROM California
- Penumbra appoints Bridget O'Rourke to board
- Adverum Biotechnologies adds Richard N. Spivey to board
- Lombard Medical appoints Kurt Lemvigh as CEO
- CareDx appoints Michael Bell as CFO
- Visa appoints John F. Lundgren as director
More inside POST
Steel Dynamics sees higher Q1 EPS Earnings
Employees want leaders on all levels Leadership